Humana (HUM)
(Delayed Data from NYSE)
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Humana and Interwell Health Expand Value-Based Support to Florida
by Zacks Equity Research
HUM and Interwell Health add Florida to their value-based kidney care program in a bid to improve health outcomes.
UnitedHealth at 19.09X P/E: Worth the Price or Time to Take Profits?
by Kaibalya Pravo Dey
With expansion into targeted markets and strategic diversification, UNH still has significant growth potential left.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Humana (HUM), Evergreen Nephrology Partner to Improve Health Outcomes
by Zacks Equity Research
HUM collaborates with Evergreen Nephrology to introduce a specialized care program for chronic kidney disease patients.
Why Is Humana (HUM) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
UnitedHealth (UNH) Rises 15% in 3 Months: Jump in or Wait out?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) expansion into targeted markets, strategic diversification and attractive dividends present significant growth opportunities.
Encompass Health (EHC) Stock Down 6% Despite Q2 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect improved net patient revenue per discharge, partly offset by higher costs. It currently estimates 2024 adjusted EPS within $3.97-$4.22, up from the earlier view of $3.86-$4.11.
Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength
by Zacks Equity Research
Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.
Compared to Estimates, Humana (HUM) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Humana (HUM) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Humana (HUM) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 18.17% and 2.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.
Insights Into Humana (HUM) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Humana (HUM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Centene (CNC) Q2 Earnings Miss Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -0.82% and 9.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina (MOH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.27% and 0.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Humana (HUM) Q2 Earnings Expected to Decline
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
by Zacks Equity Research
Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.
UnitedHealth Group (UNH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 2.26% and 0.15%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth (UNH) Pre-Q2 Earnings: Healthy Buy or a Wait-&-See?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) second-quarter earnings are likely to have benefited from higher premiums, driven by the expansion of its commercial membership base.
Company News for Jul 5, 2024
by Zacks Equity Research
Companies In The News Are: STZ, PARA, HUM, MSFT.
Humana (HUM) Ties Up With PsychArmor for Better Veteran Care
by Zacks Equity Research
Humana's (HUM) subsidiaries team up with PsychArmor to enhance veteran care, offering specialized training at 23 senior primary care centers in Texas, thereby attracting more members of the targeted community to the centers.
UnitedHealth (UNH) Stock Drops 8% YTD: Should You Hold or Fold?
by Kaibalya Pravo Dey
As commercial business improves within the industry, UnitedHealth (UNH), with its diverse portfolio of offerings, is well-positioned to capitalize on the rising demand.
Humana's (HUM) CenterWell Expands in Louisiana With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.
Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.